C. Ola Landgren, M.D., Ph.D., Conference Chair

Dr. C. Ola Landgren, Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).

Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.

He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona and a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in internal medicine at the University of Miami, FL, and a fellowship in hematology and medical oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a clinical investigator for the Damon Runyon Cancer Research Fund. He is a visiting healthcare fellow at the Goldwater Institute.

Dr. Malin Hultcrantz, MD PhD, is an Assistant Professor and board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders. Her clinical research aims to optimize treatment strategies for patients with multiple myeloma and improve patients’ quality of life. She is the principal investigator for trials involving novel immunotherapies and biomarker driven therapies. Dr. Hultcrantz has extensive experience in epidemiological research in multiple myeloma and the precursors disorders MGUS and smoldering multiple myeloma.

Dr. Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He is board certified in internal medicine, hematology and medical oncology. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an Instructor in Medicine at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Director of Myeloma and Plasma Cell Pathways at the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T-cell therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma. He also attends in the Center of Prevention of Progression (CPOP) clinic at DFCI, which is focused on management of patients with precursor plasma cell disorders.

Dr. C. Ola Landgren, Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).

Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.

He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.

Thomas G. Martin III, MD, is Director of the Hematology Malignancies Research Committee and Co-Director of the Myeloma Program at UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Martin earned his medical degree at the University of Connecticut School of Medicine. He completed internship and residency programs at Harbor-UCLA Medical Center and a fellowship in hematology/oncology at UCSF Medical Center, where he was promoted to Adjunct Professor of Medicine in the Division of Hematology and Oncology. Dr. Martin later was appointed Assistant Professor of Medicine at The University of Texas MD Anderson Cancer Center. After several years, he joined the faculty at UCSF, where he continues to serve as Professor of Clinical Medicine in the Adult Leukemia and Bone Marrow Transplantation Program. He is also currently the interim Co-Chief of the Division of Hematology/Oncology at UCSF.

Dr. Martin’s research focuses on investigating novel treatments for multiple myeloma. This includes early-phase trials of new drugs, novel combinations, and therapeutics to use with bone marrow transplantation. He has a special interest in antibody therapy for myeloma, as well as novel immunotherapies for myeloma.

A Diplomate of the American Board of Internal Medicine with subspecialty certification in hematology, Dr. Martin is a member of the American Society for Blood and Marrow Transplantation, the American Academy for the Advancement of Science, and the American Society of Hematology. Dr. Martin has authored numerous articles in the peer-reviewed literature. Additionally, he is a teacher, mentor, and a frequently invited speaker.

Dr. Martin is a member of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström’s Macroglobulinemia Panel, and a member of the International Myeloma Foundation Advisory Committee.

Dr Costa obtained a medical degree and subsequently PhD from Universidade de Sao Paulo, Brazil. He trained in Hematology and Medical Oncology at University of Colorado and in Blood and Marrow Transplantation at Mayo Clinic, Rochester- MN. He is currently Professor of Medicine and Senior Clinical Investigator at University of Alabama at Birmingham O’Neal Comprehensive Cancer Center where he also direct the Multiple Myeloma Research and Treatment Program. Dr Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma.

Martin S. Tallman, MD, has been appointed Chief of the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College.

Dr. Tallman is a renowned expert in the management and development of new treatments for patients with both acute and chronic leukemia. Internationally recognized, he has been at the forefront of several key clinical trials that have led to new standards of care.

“There has never been a more exciting time in the field of malignant hematologic diseases,” said Dr. Tallman. “Memorial Sloan Kettering Cancer Center is well positioned to take advantage of the explosion of knowledge in addressing the molecular genetics of the acute and chronic leukemias. This new information, together with the myriad of new agents available, may well provide the foundation for continued new discoveries and the development of new, effective therapies.”

In addition to his significant contributions to clinical research, Dr. Tallman has held various leadership roles in the Eastern Cooperative Oncology Group, where he chairs the Leukemia Committee, the National Comprehensive Cancer Network, the International Bone Marrow Transplant Registry, the National Bone Marrow Program, and the Leukemia Research Foundation. In addition, he serves as one of 13 associate editors for the journal Blood.

Prior to his appointment at Memorial Sloan Kettering, Dr. Tallman served as a tenured Professor of Medicine at the Northwestern University Feinberg School of Medicine and Associate Chief of the Division of Hematology/Oncology at Northwestern University. Dr. Tallman received his MD degree from Chicago Medical School. After completing housestaff training in internal medicine at Northwestern University, Dr. Tallman held a fellowship in hematology and medical oncology at the Fred Hutchinson Cancer Research Center and the University of Washington.